Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Prior treatment

• Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 90 days, whichever is longer.
• Plasma donation (≥ 400mL) within 12 weeks prior to first dosing.

Other illness

• History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer).
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.

Other

• All transplanted patients (any organ, including bone marrow).
• Pregnant or nursing (lactating) women.

• Subjects must have signed and dated an IRB/IEC approved written informed consent form.Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor biopsies, and other requirements of the study.
• Female and male patients above 18 years of age.
• Patients must weigh at least 35 kg to participate in the study, and must have a body mass index (BMI) below 35 kg/m2. BMI = Body weight (kg) / \[Height (m)\]2
• Subjects with a biopsy-verified IgA nephropathy and where the biopsy was performed within the prior ten years.
• 24h-UPCR ≥0.75g/g or 24h-UPE≥1.0g/24h at screening.
• Measured Glomerular Filtration Rate (GFR) or estimated GFR (using the CKD-EPI formula 2021) ≥30 mL/min per 1.73 m2.For patients with eGFR\* 20 to \<30ml/min/1.73m2, a qualifying biopsy performed in two years.